In the wake of a market pull in obesity nearly five years ago, the other shoe has dropped for Eisai’s serotonin 2C receptor ...
The decision in Europe follows an approval granted by the US Food and Drug Administration (FDA) in March this year.
In a new era of Alzheimer’s disease research, the emergence of blockbuster therapies like Eli Lilly’s Kisunla (donanemab) and ...
Worldcrunch on MSN5h
Leqembi, Is This New Drug The Turning Point In Curing Alzheimer’s?That Thursday, for the first time, the European Medicines Agency (EMA) approved a drug that targets the cause — not just the ...
AbbVie's $10.1 billion takeover of ImmunoGen has been rewarded with EU approval for Elahere, the first drug specifically ...
The Sleep Research Society Foundation is hosting a state-of-the-science webinar, "Lessons Learned from Central Disorders of Hypersomnolence and Future Directions," Monday, Dec. 2, from 9:30 a.m. to 11 ...
Allarity maintains a cash balance of $18.5 million, sufficient to advance and accelerate stenoparib's clinical development ...
An Osaka Metropolitan University-led team evaluated the effects of SGLT2 inhibitors in protecting the kidneys, showing that ...
The full result from Eisai’s large, global phase 3 confirmatory Clarity AD clinical study of lecanemab – an investigational anti-amyloid beta (Aβ) protofibril antibody for the treatment of ...
We were all shocked when word slipped out that Jumana Murad was a married lady! The whole deal was very quick to come to pass ...
Biogen downgraded to Hold by Needham amid projected flat revenues until 2026. Leqembi and other new product sales show ...
Needham has downgraded Biogen (BIIB) to hold from buy, citing a lack of near-term catalysts and slow uptake for the company’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback